市场调查报告书

全球置入式药物输送设备市场 - 各产品类型、技术、用途、地区 - 成长率,市场趋势,市场预测(2018年~2023年)

Implantable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 707340
出版日期 内容资讯 英文 120 Pages
商品交期: 2-3个工作天内
价格
Back to Top
全球置入式药物输送设备市场 - 各产品类型、技术、用途、地区 - 成长率,市场趋势,市场预测(2018年~2023年) Implantable Drug Delivery Devices Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 120 Pages
简介

全球置入式药物输送设备市场,预计从2018年到2023年,以7.8%的年复合成长率发展。由于基因学、蛋白质体学、生物科技领域的技术发展和新药的登场,促进置入式药物输送设备市场成长。

本报告提供全球置入式药物输送设备市场调查,市场概要,各产品类型、技术、用途、地区的市场规模的变化与预测,市场趋势,市场规模的变化与预测,市场成长要素及阻碍因素分析,市场机会,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 简介

  • 市场定义

第2章 调查方法

第3章 摘要整理

第4章 主要影响要素

第5章 置入式药物输送设备市场概要

  • 目前市场方案
  • 波特的五力分析
    • 买方议价能力
    • 供给企业谈判力
    • 新加入业者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关系

第6章 市场动态

  • 成长要素
    • 微创手术的需求高涨
    • 新产品的登场
    • 慢性疾病的盛行率的上升
  • 阻碍因素
    • 设备的成本高
    • 严格的法规方案
  • 市场机会
  • 主要课题

第7章 置入式药物输送设备市场:各市场区隔

  • 各产品类型
    • 药物输液帮浦
    • 眼内药物输送设备
    • 避孕药物输送设备
    • 支架
  • 各技术
    • 生物分解性植入
    • 非生物分解性植入
  • 各用途
    • 肿瘤学
    • 心血管
    • 自体免疫疾病
    • 妇产科
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东、非洲
    • 南美

第8章 企业简介和竞争情形

  • Abbott
  • Allergan
  • Boston Scientific Corporation
  • Bausch and Lomb Inc.
  • Delpor Inc.
  • Medtronic
  • Novartis
  • pSivida Corp.
  • Teleflex Incorporated
  • 3M's Health Care

第9章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 62809

The implantable drug delivery devices market is expected to witness robust growth due to the recent developments taking place in genomics, proteomics and biotechnology that have led to emerging classes of novel pharmaceutical compounds across the globe that helps to accelerate the market. Furthermore, an increase in the burden of chronic diseases is affecting the large patient population which increases the number of surgeries and hence drives the implantable drug delivery devices market. According to the World Health Organization (WHO) 2017, chronic diseases are the major cause of disabilities worldwide. The estimated global burden by 2020 would be 60% and moreover, 73% of deaths in 2020 is expected due to chronic diseases. However, the high cost of devices and surgery costs, low rate of adoption are the few restraining factors of the growth of implantable drug delivery devices market.

Key Market Trends

Infusion pumps segment holds significant market share

Infusion pumps are devices that are used to deliver fluids into a patient's body, in a controlled manner. They are capable of supplying medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers. Infusion pumps play an important role in delivering accurate medications in chemotherapy, for diabetics, etc., for the corresponding diseases. The rising number of diabetes cases and increasing investments in diabetes care and management have helped in the adoption of insulin infusion pumps. Technological advancements, coupled with increasing R&D initiatives on gastrointestinal disorders, cancer, neurological problems, and AIDS, are providing lucrative opportunities for infusion pumps in the market. According to the FDA, in 2017, Baxter's Sigma Spectrum Infusion pump has been the number one infusion pump in drug library compliance. Sigma Spectrum has a user interface that provides top-quality patient safety margins and has the ability to integrate with leading electronic medical record systems.

North America Dominates the Implantable Drug Delivery Devices Market

In North America, the medical device industry is a highly regulated sector of the economy. There are several studies that suggest that the US manufacturers of implantable devices can maintain high prices, in part due to structural barriers such as costly regulatory approval processes and patent protections. Therefore, manufacturers face problems in launching new products in the United States. Hospitals are the primary purchasers of most high-cost implantable devices in the United States, but they have limited bargaining power to negotiate for lower prices. There are millions of Americans being implanted with implantable devices such as artificial hips or cardiac pacemakers, in their bodies. Experts have also estimated that 7.2 million Americans are living with joint implants. However, due to the aging population and the increasing prevalence of chronic conditions, the number of patients adopting implantable devices continues to grow exponentially. During the past year, in the United States, there have been many advancements in technology and medical innovation, which have expanded the types of implantable devices, to include artificial hearts and deep-brain stimulators to control epilepsy.

Competitive Landscape

Market players are focusing on new product launches, minimizing the price of the tests in order to gain maximum traction in the global market. Furthermore, market players are concentrating on various growth strategies such as collaborations, acquisitions, partnerships to enhance their market presence. For instance, Jan 2018: Medtronic Plc has received FDA approval of a new clinician programmer for use with the SynchroMed(TM) II Intrathecal Drug Delivery system, an implantable pump that provides targeted drug delivery for chronic pain and severe spasticity. Major market players are Boston Scientific Corporation, Bausch and Lomb Inc., Delpor Inc., Medtronic, pSivida Corp. and Teleflex Incorporated among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Minimally Invasive Procedures
    • 4.2.2 Emergence of Novel Products
    • 4.2.3 Increasing Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices
    • 4.3.2 Stringent Regulatory Requirements
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Drug Infusion Pumps
    • 5.1.2 Intraocular Drug Delivery Devices
    • 5.1.3 Contraceptive Drug Delivery Devices
    • 5.1.4 Stents
    • 5.1.5 Others
  • 5.2 By Technology
    • 5.2.1 Biodegradable Implants
    • 5.2.2 Non-biodegradable Implants
  • 5.3 By Application
    • 5.3.1 Oncology
    • 5.3.2 Cardiovascular
    • 5.3.3 Autoimmune Diseases
    • 5.3.4 Obstetrics and Gynecology
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Allergan
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Bausch and Lomb Inc.
    • 6.1.4 Delpor Inc.
    • 6.1.5 Medtronic
    • 6.1.6 Novartis (Alcon)
    • 6.1.7 pSivida Corp.
    • 6.1.8 Teleflex Incorporated
    • 6.1.9 DSM Biomedical
    • 6.1.10 TissueGen, Inc.
    • 6.1.11 3M

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top